PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 260 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,720,319 | +76.1% | 56,073 | +130.1% | 0.00% | – |
| Q2 2023 | $976,666 | -19.0% | 24,374 | -17.5% | 0.00% | – |
| Q1 2023 | $1,205,976 | +14.0% | 29,551 | +7.8% | 0.00% | – |
| Q4 2022 | $1,058,146 | -3.6% | 27,406 | +32.8% | 0.00% | – |
| Q3 2022 | $1,098,000 | -15.5% | 20,643 | -7.4% | 0.00% | -100.0% |
| Q2 2022 | $1,299,000 | -20.9% | 22,285 | +3.6% | 0.00% | 0.0% |
| Q1 2022 | $1,642,000 | +15.9% | 21,521 | -8.6% | 0.00% | – |
| Q4 2021 | $1,417,000 | +0.9% | 23,548 | -6.1% | 0.00% | – |
| Q3 2021 | $1,405,000 | -34.8% | 25,081 | -29.4% | 0.00% | -100.0% |
| Q2 2021 | $2,154,000 | -36.0% | 35,503 | -26.0% | 0.00% | 0.0% |
| Q1 2021 | $3,365,000 | -8.2% | 48,003 | -21.7% | 0.00% | 0.0% |
| Q4 2020 | $3,667,000 | +145.0% | 61,286 | +146.1% | 0.00% | 0.0% |
| Q3 2020 | $1,497,000 | -25.7% | 24,902 | -35.2% | 0.00% | 0.0% |
| Q2 2020 | $2,016,000 | +27.4% | 38,418 | -18.6% | 0.00% | 0.0% |
| Q1 2020 | $1,582,000 | -53.3% | 47,183 | -36.8% | 0.00% | 0.0% |
| Q4 2019 | $3,385,000 | +398.5% | 74,712 | +318.8% | 0.00% | – |
| Q3 2019 | $679,000 | -16.7% | 17,838 | -4.8% | 0.00% | – |
| Q2 2019 | $815,000 | +29.8% | 18,738 | +13.6% | 0.00% | – |
| Q1 2019 | $628,000 | +101.9% | 16,488 | +128.2% | 0.00% | – |
| Q4 2018 | $311,000 | -24.3% | 7,224 | -13.7% | 0.00% | – |
| Q3 2018 | $411,000 | +65.7% | 8,373 | +8.0% | 0.00% | – |
| Q2 2018 | $248,000 | -76.5% | 7,752 | -77.1% | 0.00% | – |
| Q1 2018 | $1,054,000 | -12.0% | 33,836 | +29.0% | 0.00% | – |
| Q4 2017 | $1,198,000 | +33.3% | 26,236 | +9.7% | 0.00% | – |
| Q3 2017 | $899,000 | +5.9% | 23,926 | +34.3% | 0.00% | – |
| Q2 2017 | $849,000 | +28.6% | 17,809 | +23.0% | 0.00% | – |
| Q1 2017 | $660,000 | +177.3% | 14,473 | +96.8% | 0.00% | – |
| Q4 2016 | $238,000 | +40.0% | 7,356 | +48.2% | 0.00% | – |
| Q3 2016 | $170,000 | -6.1% | 4,964 | -7.6% | 0.00% | – |
| Q2 2016 | $181,000 | -41.0% | 5,372 | -7.2% | 0.00% | – |
| Q1 2016 | $307,000 | -36.4% | 5,788 | -8.0% | 0.00% | – |
| Q4 2015 | $483,000 | +98.0% | 6,289 | +5.9% | 0.00% | – |
| Q3 2015 | $244,000 | +313.6% | 5,940 | +603.8% | 0.00% | – |
| Q2 2015 | $59,000 | -95.0% | 844 | -93.6% | 0.00% | -100.0% |
| Q1 2015 | $1,172,000 | -45.5% | 13,197 | -45.6% | 0.00% | 0.0% |
| Q4 2014 | $2,151,000 | – | 24,267 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |